Cytek Biosciences (CTKB) Profit After Tax Growth (1y) (2021 - 2026)

Cytek Biosciences (CTKB) Profit After Tax Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (1y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn -18.72%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 13.91%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 16.04%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 99.26%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn 4.70%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 89.28%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -27.13%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 108.33%
10 Cytek Biosciences 565.66 Mn 499.96 Mn 21.25 Mn -65.46%

Historic Data

Download Data
DateValue
Mar 31, 2026 -65.46%
Dec 31, 2025 -503.15%
Sep 30, 2025 -473.40%
Jun 30, 2025 46.49%
Mar 31, 2025 -84.83%
Dec 31, 2024 98.67%
Sep 30, 2024 119.71%
Jun 30, 2024 -137.78%
Mar 31, 2024 9.37%
Dec 31, 2023 55.94%
Sep 30, 2023 -823.04%
Jun 30, 2023 -525.07%
Mar 31, 2023 -215.43%
Dec 31, 2022 1,159.76%
Sep 30, 2022 150.87%
Jun 30, 2022 -126.29%
Mar 31, 2022 -2,215.69%
Dec 31, 2021 -105.95%
Sep 30, 2021 -94.71%
Jun 30, 2021 -67.08%